Shots: Censa to receive $10M in cash and up to 850,000 shares of PTC’s common stock as up front, $217.5M as development and regulatory milestones for two advanced programs along […]readmore
Tags : Rare Disease Portfolio
Shots: Therachon gains exclusive commercialization and development rights to apraglutide, initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with […]readmore